KR102469733B1 - Composition for preventing or treating respiratory disease comprising chia seeds extracts - Google Patents
Composition for preventing or treating respiratory disease comprising chia seeds extracts Download PDFInfo
- Publication number
- KR102469733B1 KR102469733B1 KR1020220029612A KR20220029612A KR102469733B1 KR 102469733 B1 KR102469733 B1 KR 102469733B1 KR 1020220029612 A KR1020220029612 A KR 1020220029612A KR 20220029612 A KR20220029612 A KR 20220029612A KR 102469733 B1 KR102469733 B1 KR 102469733B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- chia seed
- preventing
- present
- active ingredient
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 57
- 235000020235 chia seed Nutrition 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 208000023504 respiratory system disease Diseases 0.000 title abstract description 34
- 239000004480 active ingredient Substances 0.000 claims abstract description 22
- 239000003674 animal food additive Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 206010035664 Pneumonia Diseases 0.000 claims description 14
- 208000006673 asthma Diseases 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 8
- 206010036790 Productive cough Diseases 0.000 claims description 7
- 235000013376 functional food Nutrition 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- 208000024794 sputum Diseases 0.000 claims description 7
- 210000003802 sputum Anatomy 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 claims 3
- 208000026435 phlegm Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 20
- 235000015872 dietary supplement Nutrition 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004202 respiratory function Effects 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 7
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 240000005481 Salvia hispanica Species 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 235000001498 Salvia hispanica Nutrition 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 210000000621 bronchi Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 239000003172 expectorant agent Substances 0.000 description 5
- 230000003419 expectorant effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010006482 Bronchospasm Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000007885 bronchoconstriction Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 150000002617 leukotrienes Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229940092253 ovalbumin Drugs 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229960005127 montelukast Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 3
- 229950005741 rolipram Drugs 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 206010014568 Empyema Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 201000008197 Laryngitis Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 2
- 208000000017 Solitary Pulmonary Nodule Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 229960005174 ambroxol Drugs 0.000 description 2
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000002143 bronchus adenoma Diseases 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- 229960004484 carbachol Drugs 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 235000014167 chia Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- -1 for example Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- 201000003144 pneumothorax Diseases 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- GWNVDXQDILPJIG-CCHJCNDSSA-N 11-trans-Leukotriene C4 Chemical compound CCCCC\C=C/C\C=C\C=C\C=C\[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-CCHJCNDSSA-N 0.000 description 1
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 235000002912 Salvia officinalis Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 210000003678 bronchial smooth muscle cell Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229940112950 sage extract Drugs 0.000 description 1
- 235000020752 sage extract Nutrition 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 치아시드 추출물을 유효성분으로 포함하는 호흡기 질환 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating respiratory diseases comprising a chia seed extract as an active ingredient.
반려동물을 가족처럼 여기는 사람들을 일컫는 ‘펫팸족(Pet+Family)’이 최근 1,500만 명을 돌파하였으며, KB경제연구소가 발표한 2021 한국 반려동물 보고서에 따르면 반려동물을 기르는 반려가구는 604만 가구로, 한국 전체 가구의 29.7%에 달한다. 이와 더불어 반려동물의 수와 종의 다양성 또한 증가하고 있으며, 최근에는 반려동물의 신체에 직접적인 영향을 미치는 사료나 간식에 대한 관심과 이해가 높아짐에 따라 단순히 일반 사료가 아닌 영양성분 및 기능성이 포함된 사료의 공급이 일반화되고 있다.The number of 'Pet+Family', which refers to people who treat companion animals as family, recently exceeded 15 million, and according to the 2021 Korea Companion Animal Report released by KB Economic Research Institute, there are 6.04 million households raising companion animals. , accounting for 29.7% of all households in Korea. In addition, the number of companion animals and the diversity of species are also increasing. Recently, as interest in and understanding of feed or snacks that directly affect the body of companion animals has increased, products containing nutrients and functionalities, not simply general feed, have increased. Feeding is becoming commonplace.
반려동물에게서 호흡기 질환은 주요 발병 질환 중 하나이며, 보호자들도 잘 인식하고 있는 질환으로, 결막염, 부비동염, 비염, 유연, 구강궤양 등의 다양하고 광범위한 임상증상을 보일 수 있다. 원인으로는 세균, 바이러스, 곰팡이와 같은 감염성 병원체와 알러지, 비강 내 종양, 폴립, 이물과 같은 비감염성 요인을 들 수 있으며, 초기에 치료를 받지 못할 경우 생명을 위협하는 응급상황을 초래하기 쉬워 적절한 사료의 공급이 더욱 중요하다.Respiratory disease in companion animals is one of the major onset diseases, and it is a disease well recognized by guardians, and can show a wide range of clinical symptoms such as conjunctivitis, sinusitis, rhinitis, suppuration, and oral ulcers. Causes include infectious pathogens such as bacteria, viruses, and fungi, and non-infectious factors such as allergies, intranasal tumors, polyps, and foreign bodies. Feed supply is more important.
호흡기 질환은 호흡과 관련이 있는 기관인 비강, 인두, 후두, 기관, 기관지, 폐, 흉곽, 횡격막 등에 영향을 주는 질병을 의미하며, 호흡계는 외부 환경에 노출되어 있어 공기 중에 존재하는 유해물질에 쉽게 노출되기 때문에 건조한 봄이나 겨울철에 특히 많이 발생한다. 호흡기 질환은 주로 면역력 저하, 염증 작용, 세균이나 바이러스의 감염, 미세먼지 또는 흡연 등으로 인한 유해입자의 흡입 및 노화 등에 의해 발생할 수 있으며, 증상이 가벼운 것에서부터 사망에 이르기까지 매우 다양하다.Respiratory diseases refer to diseases that affect organs related to breathing such as the nasal cavity, pharynx, larynx, trachea, bronchi, lungs, chest, and diaphragm. The respiratory system is exposed to the external environment and is easily exposed to harmful substances present in the air. Because of this, it is especially common in the dry spring or winter months. Respiratory diseases can mainly be caused by reduced immunity, inflammatory action, bacterial or viral infection, inhalation of harmful particles caused by fine dust or smoking, and aging, and the symptoms vary from mild to fatal.
대표적인 호흡기 질환으로는 폐렴, 비염, 천식, 기관지염, 결핵, 만성폐쇄성폐질환 등이 있으며, 그중 천식은 알레르기염증에 의해 기관지가 반복적으로 좁아지는 만성호흡기 질환으로, 기관지가 좁아져서 숨이 차고, 기침이 나며, 가슴이 답답해지는 증상이 반복적으로 되풀이된다. 우리나라 성인 인구의 5% 정도가 천식을 앓는 것으로 알려져 있으며, 최근 전 세계적으로 천식 환자 수가 증가하고 있다. 또한, 미세먼지 증가 및 흡연으로 인해 만성폐쇄성폐질환(COPD) 환자 수가 늘고 있으며, 만성폐쇄성폐질환은 서서히 진행되며, 처음에는 가벼운 호흡곤란과 기침이 간혹 나타나지만 병이 진행되면 호흡곤란이 심해지고, 말기에는 심장기능도 떨어ㅈ지게 된다.Representative respiratory diseases include pneumonia, rhinitis, asthma, bronchitis, tuberculosis, chronic obstructive pulmonary disease, etc. Among them, asthma is a chronic respiratory disease in which the bronchi are repeatedly narrowed due to allergic inflammation. , and symptoms of chest tightness recur repeatedly. About 5% of the adult population in Korea is known to suffer from asthma, and the number of asthma patients is increasing worldwide. In addition, the number of patients with chronic obstructive pulmonary disease (COPD) is increasing due to the increase in fine dust and smoking, and chronic obstructive pulmonary disease (COPD) progresses slowly. In late stages, cardiac function also declines.
이러한 호흡기 질환의 치료제는 주로 항염증 작용이나 기도 확장 효과를 타깃으로 개발되고 있다. 항염증 또는 기도 확장 효과를 나타내는 호흡기 질환 치료제로는 당질코르티코이드 스테로이드 약물(glucocorticoid steroid drug), 베타2-아드레날린 수용체 효능제(beta2-adrenergic receptor agonist), 항류코트리엔제(leukotriene receptor antagonist) 및 포스포디에스테라아제-4 억제제(phosphodiesterase-4 inhibitor, PDE4 inhibitor) 등이 있다. 그러나 이러한 기존의 호흡기 질환 치료제들은 치료 목적이 유아 또는 소아 대상의 알레르기성 천식 및 흡연자 대상의 만성폐쇄성폐질환(COPD)에 한정되어 있으며, 상기 치료제들 대부분이 증상 완화만을 목적으로 하며, 호흡기 질환의 본질적인 원인을 제거하여 병의 진행을 늦추거나 멈추지 못하는 한계가 있다. 또한, 대다수의 호흡기 질환은 그 원인과 증상이 복합적으로 나타나므로 단일 성분, 단일 치료기전을 이용한 종래의 치료제로는 적합한 치료가 불가능한 실정임에 따라 보다 다각적이면서 복합적으로 호흡기 질환을 예방 및 치료하기 위한 새로운 치료제의 개발이 절실히 요구되고 있다. 특히, 호흡기 질환이 발병하기 전에 섭취가 용이하여 지속적으로 섭취함에 따라 용이하게 예방할 수 있고 부작용이 없는 새로운 물질의 개발이 필요한 실정이다.Treatments for these respiratory diseases are mainly being developed targeting anti-inflammatory action or airway expansion effect. Respiratory disease drugs that exhibit anti-inflammatory or airway dilating effects include glucocorticoid steroid drugs, beta2-adrenergic receptor agonists, leukotriene receptor antagonists, and phosphodiesterases. -4 inhibitors (phosphodiesterase-4 inhibitor, PDE4 inhibitor), etc. However, these existing respiratory disease treatments are limited to allergic asthma in infants or children and chronic obstructive pulmonary disease (COPD) in smokers, and most of the treatments are aimed only at relieving symptoms, There is a limit to slowing down or stopping the progression of the disease by removing the essential cause. In addition, since the majority of respiratory diseases have complex causes and symptoms, conventional treatments using a single component and a single treatment mechanism are impossible to treat appropriately, so to prevent and treat respiratory diseases more diversified and complex. There is an urgent need for the development of new therapies. In particular, there is a need to develop a new substance that can be easily prevented as it is easily ingested before the onset of respiratory diseases and has no side effects as it is continuously ingested.
한편, 치아시드(Salvia hispanica, Chia seed)는 쌍떡잎식물 통화식물목 꿀풀과 치아의 씨앗으로 멕시코 중남부 지방과 괴테말라가 원산지이다. 치아(Chia)는 일년생 허브로 꽃은 자주색 또는 흰색이며, 가지의 끝 부분에서 송이로 자라는 치아는 상업적으로 널리 알려진 씨앗 생산을 위해 재배한다. 치아시드는 오메가3, 식이섬유, 무기질과 단백질 및 다양한 아미노산 등 각종 영양소가 풍부하여 새로운 슈퍼푸드로 주목받고 있으며, 적은 양을 섭취해도 포만감을 느낄 수 있어 다이어트 식품으로도 많이 활용되고 있다. 고대 미얀마인들이 즐겨 먹었던 식재료로, 물에 넣으면 부피가 10-12배 정도 불어나는 것이 특징이다. 또한, 섬유소가 풍부하게 함유되어 있고, 소화를 도우며, 혈당 조절에도 도움을 준다. 우유보다 많은 칼슘을 함유하고 있어 뼈 건강에도 좋으며, 오메가3 지방산도 풍부해 콜레스테롤을 줄여주고 혈압을 낮추는 데 도움이 된다. 치아시드에 다량 함유되어 있는 α-리놀렌 산에는 오메가3의 공통기능 이외에도 체내로 섭쉬되면서 EPA와 DHA로 변환되고 중성지방이나 나쁜 콜레스테롤을 저하시키는 역할을 함으로써 순환기나 호흡기, 심혈관 질환의 초기 예방이 가능하며, 고혈압을 억제할 수 있다.On the other hand, chia seed ( Salvia hispanica , Chia seed) is a dicotyledonous plant, a seed of Lamiaceae Chia, and is native to central and southern Mexico and Gotemala. Chia is an annual herb with purple or white flowers. Chia, which grows in clusters at the ends of branches, is commercially grown for its well-known seeds. Chia seeds are attracting attention as a new super food because they are rich in various nutrients such as
이에 본 발명자들은 장기간 섭취해도 안전한 식품 소재 및 약재로부터 호흡기 질환의 예방, 개선 및 치료에 효과가 있는 물질을 탐색하는 과정에서, 치아시드가 호흡기 질환의 예방, 개선 및 치료에 우수한 효과가 있음을 알아내어 본 발명을 완성하였다.Accordingly, the inventors of the present invention found that chia seeds are effective in preventing, improving, and treating respiratory diseases in the process of searching for substances effective in preventing, improving, and treating respiratory diseases from food materials and medicines that are safe for long-term consumption. completed the present invention.
본 발명의 목적은 치아시드 추출물을 유효성분으로 포함함으로써 호흡기 질환을 예방 또는 치료할 수 있는 약학 조성물을 제공하는 것이다.An object of the present invention is to provide a pharmaceutical composition capable of preventing or treating respiratory diseases by containing chia seed extract as an active ingredient.
또한, 본 발명의 목적은 일상 생활에서 편리하게 섭취 가능하며, 질환 발병 전 용이하게 질환을 예방하고, 발병 후에는 지속적인 섭취로 질환을 개선시킬 수 있는 건강기능식품을 제공하는 것이다.In addition, an object of the present invention is to provide a health functional food that can be conveniently consumed in daily life, easily prevents diseases before the onset of diseases, and improves diseases by continuous intake after the onset of diseases.
또한, 본 발명의 목적은 호흡기 질환의 예방, 개선 또는 치료용 사료 조성물을 제공하는 것이다.In addition, an object of the present invention is to provide a feed composition for preventing, improving or treating respiratory diseases.
또한, 본 발명의 목적은 호흡기 질환의 예방, 개선 또는 치료용 사료첨가제 조성물을 제공하는 것이다.In addition, an object of the present invention is to provide a feed additive composition for preventing, improving or treating respiratory diseases.
본 발명은 상기 목적을 달성하기 위하여 치아시드 추출물을 유효성분으로 포함하는 호흡기 질환 예방 또는 치료용 약학 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating respiratory diseases comprising chia seed extract as an active ingredient.
상기 조성물 총 중량에 대하여, 상기 치아시드 추출물을 0.001 내지 90 중량%로 포함할 수 있으며, 상기 추출물은 물, C1~C6의 직쇄 또는 분지형 알코올, 아세톤, 에테르, 벤젠, 클로로포름, 에틸아세테이트, 메틸렌클로라이드, 헥산, 시클로헥산, 석유에테르(petroleum ether), 아임계 유체, 및 초임계 유체로 이루어진 군으로부터 선택된 하나 이상의 용매에 의한 추출물일 수 있다.Based on the total weight of the composition, the chia seed extract may be included in an amount of 0.001 to 90% by weight, and the extract may include water, C 1 to C 6 straight-chain or branched alcohol, acetone, ether, benzene, chloroform, ethyl acetate, It may be an extract by one or more solvents selected from the group consisting of methylene chloride, hexane, cyclohexane, petroleum ether (petroleum ether), subcritical fluid, and supercritical fluid.
상기 호흡기 질환은 기침, 가래, 감기, 독감, 천식, 폐렴, 기흉, 결핵, 만성폐쇄성폐질환, 알레르기비염, 기관지염, 인후염, 편도염, 후두염, 천명성 유아증후군, 폐기종, 기관지 선종, 고립성 폐결절, 폐결핵, 농흉, 폐농양 또는 폐의 조직구 증식증을 포함한다.The respiratory diseases include cough, sputum, cold, flu, asthma, pneumonia, pneumothorax, tuberculosis, chronic obstructive pulmonary disease, allergic rhinitis, bronchitis, sore throat, tonsillitis, laryngitis, wheezing infant syndrome, emphysema, bronchial adenoma, solitary pulmonary nodule, pulmonary tuberculosis , empyema, lung abscess or histiocytic hyperplasia of the lung.
또한, 본 발명은 치아시드 추출물을 유효성분으로 포함하는 호흡기 질환 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for preventing or improving respiratory diseases comprising chia seed extract as an active ingredient.
또한, 본 발명은 치아시드 추출물을 유효성분으로 포함하는 호흡기 질환 예방, 개선 또는 치료용 사료 조성물을 제공한다.In addition, the present invention provides a feed composition for preventing, improving or treating respiratory diseases comprising chia seed extract as an active ingredient.
또한, 본 발명은 치아시드 추출물을 유효성분으로 포함하는 호흡기 질환 예방, 개선 또는 치료용 사료첨가제 조성물을 제공한다.In addition, the present invention provides a feed additive composition for preventing, improving or treating respiratory diseases comprising chia seed extract as an active ingredient.
상기 사료첨가제는 분말제, 정제, 캡슐제, 환제 또는 액제일 수 있다.The feed additive may be a powder, tablet, capsule, pill or liquid.
본 발명의 조성물은 치아시드 추출물을 유효성분으로 포함함에 따라 천식 주요 기전인 루코트리엔을 생성하는 효소인 5-리폭시게나제 활성을 억제하고, 천식 등 호흡기 질환 환자의 기관지 평활근 세포의 증식을 유의적으로 억제하는 효과가 있으며, 거담작용 및 폐염증 억제 활성 효과가 있어 호흡기 질환의 예방, 개선 또는 치료용 조성물로서 매우 효과적이다.As the composition of the present invention contains chia seed extract as an active ingredient, it inhibits the activity of 5-lipoxygenase, an enzyme that produces leukotrienes, a major mechanism of asthma, and notices the proliferation of bronchial smooth muscle cells in patients with respiratory diseases such as asthma. It has the effect of suppressing the negative effect, and has expectorant action and pulmonary inflammation inhibitory activity, so it is very effective as a composition for preventing, improving or treating respiratory diseases.
또한, 치아시드 추출물은 천연소재로서 부작용이 없고, 장기간 복용시에도 인체에 무해하고 안전하다.In addition, chia seed extract has no side effects as a natural material, and is harmless and safe to the human body even when taken for a long time.
도 1은 본 발명의 일 실시예에 따른 폐염증 억제 활성 평가에서 폐로 유입되는 총 세포 수를 나타낸 그래프이다.
도 2는 본 발명의 일 실시예에 따른 폐염증 억제 활성 평가에서 BALF 내 marophage 수를 나타낸 그래프이다.
도 3은 본 발명의 일 실시예에 따른 폐염증 억제 활성 평가에서 BALF 내 neutrophil 수를 나타낸 그래프이다.
도 4는 본 발명의 일 실시예에 따른 치아시드 추출물의 대식세포(Raw264.7)에 대한 세포독성 분석 결과를 나타낸다.1 is a graph showing the total number of cells entering the lungs in the evaluation of pulmonary inflammation inhibitory activity according to an embodiment of the present invention.
Figure 2 is a graph showing the number of marophage in BALF in the evaluation of pulmonary inflammation inhibitory activity according to an embodiment of the present invention.
Figure 3 is a graph showing the number of neutrophils in BALF in the lung inflammation inhibitory activity evaluation according to an embodiment of the present invention.
Figure 4 shows the results of cytotoxicity analysis on macrophages (Raw264.7) of chia seed extract according to an embodiment of the present invention.
이하, 본 발명에 대해 더 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명에서 사용되는 용어 “추출물”은 식물의 추출 처리에 의하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다.The term "extract" used in the present invention refers to an extract obtained by extraction treatment of a plant, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, a crude or purified product of the extract, or a mixture thereof, etc. and extracts of all formulations that can be formed using the extract solution.
본 발명에서 사용되는 용어 “예방”은 본 발명의 조성물의 투여로 특정 질환의 증상을 억제하거나 진행을 지연시키는 모든 행위를 의미한다.As used herein, the term "prevention" refers to any action that suppresses symptoms or delays the progression of a specific disease by administering the composition of the present invention.
본 발명에서 사용되는 용어 “치료”는 본 발명의 조성물의 투여로 특정 질환의 증상을 호전 또는 이롭게 변경시키는 모든 행위를 의미한다.The term "treatment" used in the present invention refers to all activities that improve or beneficially change the symptoms of a specific disease by administering the composition of the present invention.
본 발명은 치아시드 추출물을 유효성분으로 포함하는 호흡기 질환 예방 또는 치료용 약학 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating respiratory diseases comprising chia seed extract as an active ingredient.
본 발명에 사용된 치아시드 추출물은 치아시드로부터 침출 또는 전출하여 얻은 침출액, 또는 침출액을 다시 일부 또는 전부 농축하여 얻은 농축물, 또는 다시 그 농축물을 건조시켜 제조한 침제, 전제, 정기, 유동엑기스(이하 추출 엑기스라 함)를 포함한다.The chia seed extract used in the present invention is a leachate obtained by leaching or transferring from chia seeds, or a concentrate obtained by concentrating some or all of the leachate again, or a precipitate, precipitate, regular, fluidized extract prepared by drying the concentrate again (hereinafter referred to as an extraction extract).
또한, 상기 치아시드 추출물은 통상의 방법을 통하여 유효성분을 추출한 추출물일 수 있다.In addition, the chia seed extract may be an extract obtained by extracting an active ingredient through a conventional method.
상기 추출의 구체적인 일 예로, 치아시드를 잘게 분쇄하고 분쇄물 건조중량에 대해 추출 용매로서 물, C1~C6의 직쇄 또는 분지형 알코올, 물과 직쇄 또는 분지형 알코올의 혼합물, 아세톤, 1,3-부틸렌 글리콜, 노말 프로판올, 이소프로판올, 노말 부탄올 등의 극성용매와 이들의 혼합용매를 5배 내지 20배 부피량을 가하여 침적 추출하여 여과한 후 여액을 감압농축하는 것일 수 있다. 또한, 상기 추출 과정을 반복하여 수행할 수 있는데, 일 예로, 감압농축하여 얻어진 농축액에 물을 가하여 분산시킨 후 분산액에 동량의 에칠아세테이트, 클로로포름, 디에칠에테르 등의 저극성 유기용매를 가하고 진탕한 후 유기층을 분리하고 감압농축하여 활성이 우수한 추출물을 얻을 수 있다.As a specific example of the extraction, finely pulverized chia seeds, water, C 1 ~ C 6 straight-chain or branched alcohol, a mixture of water and straight-chain or branched alcohol, acetone, 1,3 -Polar solvents such as butylene glycol, normal propanol, isopropanol, and normal butanol and mixed solvents thereof may be added in a volumetric amount of 5 to 20 times, extracted by immersion, filtered, and then the filtrate is concentrated under reduced pressure. In addition, the extraction process may be repeatedly performed. For example, water is added to the concentrate obtained by concentration under reduced pressure to disperse, and then an equal amount of a low-polarity organic solvent such as ethyl acetate, chloroform, and diethyl ether is added to the dispersion and shaken. After separating the organic layer and concentrating under reduced pressure, an extract having excellent activity can be obtained.
이와 같이 2차에 걸쳐 추출함으로써 추출 효율을 높일 수 있으나 본 발명의 추출물이 추출 회수에 한정되는 것은 아니다.Extraction efficiency can be increased by extracting twice as described above, but the extract of the present invention is not limited to the number of extractions.
상기 치아시드 추출물 제조시 치아시드 분쇄물 중량 대비 사용되는 용매의 양이 너무 적으면 교반이 어렵고 추출물의 용해도가 낮아져 추출 효율이 떨어질 수 있으며, 용매의 양이 지나치게 많은 경우 정제 단계에서 사용되는 저급 알코올의 사용량이 많아져 경제성이 저하되며 취급상 문제가 발생할 수 있으므로 상기 용매의 사용량 범위로 사용하는 것이 좋다.If the amount of the solvent used relative to the weight of the chia seed pulverized material is too small in the preparation of the chia seed extract, stirring may be difficult and the solubility of the extract may decrease, resulting in a decrease in extraction efficiency. If the amount of the solvent is too large, the amount of lower alcohol used in the purification step This increases the economic efficiency and may cause problems in handling, so it is preferable to use the solvent within the range of usage.
추출물의 추출방법으로는 냉침과 페르콜레이션의 경우는 약 12시간 내지 96시간, 또는 C1~C6의 직쇄 또는 분지형 알코올, 에칠아세테이트 또는 디에칠에테르를 용매로 하여 4℃ 내지 25℃의 상온에서 3일 내지 20일 방치 숙성시켜서 유효성분을 추출할 수도 있으며, 온침의 경우는 사용하는 용매 등의 종류와 온도에 따라서 상이하나 적당한 것은 용매의 환류 온도에 가까운 온도로 5시간 내지 24시간 정도를 행할 수 있으나, 이에 제한되는 것은 아니다.As for the extraction method of the extract, in the case of cooling and percolation, about 12 hours to 96 hours, or C 1 ~ C 6 straight-chain or branched alcohol, ethyl acetate or diethyl ether as a solvent at 4 ° C to 25 ° C Active ingredients can be extracted by aging at room temperature for 3 to 20 days. In the case of warm acupuncture, it varies depending on the type and temperature of the solvent used, but suitable is about 5 to 24 hours at a temperature close to the reflux temperature of the solvent. It can be done, but is not limited thereto.
상기와 같이 제조된 치아시드 추출물은 조성물 총 중량을 기준으로 0.001 내지 90 중량% 포함될 수 있으나, 이에 제한되는 것은 아니며, 환자의 상태 및 질환의 종류 및 진행 정도에 따라 변할 수 있다. 0.001 중량% 미만의 농도에서는 뚜렷한 효과를 기대할 수 없으며, 90 중량%를 초과하는 경우 효과 대비 경제성이 저하될 수 있다. 일 예로, 바람직하게는 0.01 내지 50 중량%로 포함되는 것일 수 있다.The chia seed extract prepared as above may be included in an amount of 0.001 to 90% by weight based on the total weight of the composition, but is not limited thereto, and may vary depending on the patient's condition and the type and progress of the disease. At a concentration of less than 0.001% by weight, a clear effect cannot be expected, and when it exceeds 90% by weight, the effect versus economic efficiency may be reduced. For example, it may be preferably included in 0.01 to 50% by weight.
본 발명의 조성물은 유효성분 이외에 약제학적으로 허용되는 담체를 포함하여 당업계에 공지된 통상의 방법으로 투여 경로에 따라 경구용 제형 또는 비경구용 제형으로 제조될 수 있다. 여기서 투여 경로는 국소 경로, 경구 경로, 정맥 내 경로, 근육 내 경로, 및 점막 조직을 통한 직접 흡수를 포함하는 임의의 적절한 경로일 수 있으며, 두 가지 이상의 경로를 조합하여 사용할 수도 있다. 두 가지 이상 경로의 조합의 예는 투여 경로에 따른 두 가지 이상의 제형의 약물이 조합된 경우로서 예컨대 1차로 어느 한 약물은 정맥 내 경로로 투여하고 2차로 다른 약물은 국소 경로로 투여하는 경우이다.The composition of the present invention may be formulated into an oral formulation or a parenteral formulation according to the route of administration by a conventional method known in the art, including a pharmaceutically acceptable carrier in addition to the active ingredient. The route of administration herein may be any appropriate route including topical route, oral route, intravenous route, intramuscular route, and direct absorption through mucosal tissue, and two or more routes may be used in combination. An example of a combination of two or more routes is a case in which two or more formulations of drugs are combined according to the route of administration, for example, one drug is firstly administered intravenously and the other drug is secondly administered through a topical route.
본 발명의 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있으며, 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘 카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween), 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.The composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions according to conventional methods, respectively. , Carriers, excipients and diluents that may be included in the composition comprising the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicates, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one excipient, for example, starch, calcium carbonate, sucrose ( It is prepared by mixing sucrose, lactose, or gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, solutions for oral use, emulsions, and syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As the base of the suppository, witepsol, macrogol, tween, cacao butter, laurin paper, glycerogeratin and the like may be used.
상기 유효성분의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 상기 유효성분은 1일 1 mg/kg 내지 1000 mg/kg, 바람직하게는 50 mg/kg 내지 500 mg/kg, 보다 바람직하게는 150 mg/kg 내지 300 mg/kg으로 투여하는 것이 좋다. 투여는 하루에 한 번 투여할 수도 있고, 수회 나누어 투여할 수 있다. 따라서, 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dose of the active ingredient varies depending on the condition and weight of the patient, the severity of the disease, the type of drug, the route and duration of administration, but can be appropriately selected by those skilled in the art. However, for a desirable effect, the active ingredient is administered at 1 mg/kg to 1000 mg/kg, preferably 50 mg/kg to 500 mg/kg, and more preferably 150 mg/kg to 300 mg/kg per day. It is good to do. Administration may be administered once a day, or may be administered in several divided doses. Accordingly, the dosage is not intended to limit the scope of the present invention in any way.
본 발명의 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막(intracerebroventricular) 또는 뇌혈관내 주사에 의해 투여될 수 있다.The composition of the present invention can be administered to mammals such as rats, mice, livestock, and humans through various routes. All modes of administration are contemplated, eg oral, rectal or intravenous, intramuscular, subcutaneous, intracerebral (intracerebroventricular) or intracerebrovascular injection.
본 발명에 따른 조성물은 치아시드 추출물을 유효성분으로 포함함으로써 진해작용, 거담작용, 항염증 작용 등의 효과를 가지며, 이로써 호흡기 질환의 예방 또는 치료 효과를 갖는다.The composition according to the present invention has effects such as antitussive action, expectorant action, and anti-inflammatory action by including chia seed extract as an active ingredient, thereby having an effect of preventing or treating respiratory diseases.
본 발명의 치아시드 추출물은 호흡기 질환 예방 또는 개선을 위한 약제, 식품 및 음료 등에 다양하게 이용될 수 있다. 상기 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다.The chia seed extract of the present invention can be used in various ways such as pharmaceuticals, foods, and beverages for preventing or improving respiratory diseases. Examples of the food include various foods, beverages, gum, tea, vitamin complexes, health supplements, and the like, and may be used in the form of powder, granule, tablet, capsule, or beverage.
본 발명의 치아시드 추출물 자체는 독성 및 부작용은 거의 없으므로 예방 목적으로 장기간 복용 시에도 안심하고 사용할 수 있다.The chia seed extract of the present invention itself has little toxicity and side effects, so it can be safely used even when taken for a long period of time for preventive purposes.
상기 호흡기 질환은 기침, 가래, 감기, 독감, 천식, 폐렴, 기흉, 결핵, 만성폐쇄성폐질환, 알레르기비염, 기관지염, 인후염, 편도염, 후두염, 천명성 유아증후군, 폐기종, 기관지 선종, 고립성 폐결절, 폐결핵, 농흉, 폐농양 또는 폐의 조직구 증식증을 포함을 포함하며, 이에 제한되는 것은 아니다.The respiratory diseases include cough, sputum, cold, flu, asthma, pneumonia, pneumothorax, tuberculosis, chronic obstructive pulmonary disease, allergic rhinitis, bronchitis, sore throat, tonsillitis, laryngitis, wheezing infant syndrome, emphysema, bronchial adenoma, solitary pulmonary nodule, pulmonary tuberculosis , including, but not limited to, empyema, lung abscess or histiocytosis of the lung.
또한, 다른 측면에서 본 발명은 치아시드 추출물을 유효성분으로 포함하는 호흡기 질환 예방 또는 개선용 건강기능식품을 제공한다.In another aspect, the present invention provides a health functional food for preventing or improving respiratory diseases comprising chia seed extract as an active ingredient.
또한, 본 발명의 건강기능식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강기능식품은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 건강기능식품의 전체 조성물 100 중량부에 대하여 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition, the health functional food of the present invention is various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, and the like. In addition, the health functional food of the present invention may contain fruit flesh for the production of natural fruit juice, fruit juice beverages and vegetable beverages. These components may be used independently or in combination. The ratio of these additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight based on 100 parts by weight of the total composition of the health functional food of the present invention.
또한, 본 발명은 치아시드 추출물을 유효성분으로 포함하는 호흡기 질환 예방, 개선 또는 치료용 사료첨가제 조성물을 제공한다.In addition, the present invention provides a feed additive composition for preventing, improving or treating respiratory diseases comprising chia seed extract as an active ingredient.
상기 사료첨가제는 분말제, 정제, 캡슐제, 환제 또는 액제일 수 있으나, 이에 제한되는 것은 아니다.The feed additive may be a powder, tablet, capsule, pill or liquid, but is not limited thereto.
이하, 본 발명을 실시예 및 실험예를 참조하여 설명한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예 및 실험예에 한정되는 것은 아니다.Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. These examples are only for explaining the present invention in more detail, and the scope of the present invention is not limited to these examples and experimental examples according to the gist of the present invention.
<실시예 1> 치아시드 추출물 제조<Example 1> Preparation of chia seed extract
치아시드(Salvia hispanica) 분말에 10배 중량의 50% 에탄올을 가하여 실온에서 24시간 동안 추출한 후 여과한 여액을 rotary vacuum evaporator (EYELA, Japan)로 농축하여 치아시드 추출물을 제조하였다.Chia seed ( Salvia hispanica ) 10 times the weight of 50% ethanol was added to the powder, extracted at room temperature for 24 hours, and the filtered filtrate was concentrated with a rotary vacuum evaporator (EYELA, Japan) to prepare a chia seed extract.
<실시예 2> 치아시드 추출물 제조<Example 2> Preparation of chia seed extract
치아시드(Salvia hispanica) 분말에 10배 중량의 물을 가하여 60~70℃에서 24시간 동안 추출한 후 여과한 여액을 rotary vacuum evaporator (EYELA, Japan)로 농축하여 치아시드 추출물을 제조하였다.Chia seed ( Salvia hispanica ) After adding 10 times the weight of water to powder and extracting at 60-70 ° C. for 24 hours, the filtered filtrate was concentrated with a rotary vacuum evaporator (EYELA, Japan) to prepare a chia seed extract.
<실시예 3> 세이지 추출물 제조<Example 3> Preparation of sage extract
치아시드 분말 대신 세이지(Salvia officinalis) 분말을 이용하여 상기 실시예 1과 동일하게 제조하였다.It was prepared in the same manner as in Example 1 using sage ( Salvia officinalis ) powder instead of chia seed powder.
<실험예 1> 5-리폭시게나제 억제 활성 평가<Experimental Example 1> Evaluation of 5-lipoxygenase inhibitory activity
5-리폭시게나아제는 천식 주요 발병 기전인 루코트리엔 생성 효소로서, 5-리폭시게나아제 활성 억제 효과를 평가하였다. 먼저, 랫트 호염기구성 백혈병 세포(Rat basophilic leukemia cell, RBL-1)를 혈청이 포함되지 않는 RPMI 배지를 이용하여 37℃로 안정화시킨 후 시험물질을 넣고 기질로 아라키돈산(arachidonic acid)을 넣어 15분간 루코트리엔을 생성시켰다. 생성된 루코트리엔의 양은 시스테이닐 루코트리엔 EIA 키트(cysteinyl leukotriene EIA kit)를 이용해 측정하였다. 양성대조군으로는 5-리폭시게나제 저해제인 지루톤(zileuton) 및 몬테루카스트(montelukast)를 사용하였다.5-Lipoxygenase is an enzyme that produces leukotriene, which is a major pathogenesis of asthma, and the inhibitory effect of 5-lipoxygenase activity was evaluated. First, after stabilizing rat basophilic leukemia cells (RBL-1) at 37°C using RPMI medium that does not contain serum, a test substance was added and arachidonic acid was added as a substrate for 15 minutes to produce leukotriene. The amount of leukotriene produced was measured using a cysteinyl leukotriene EIA kit. As a positive control, 5-lipoxygenase inhibitors zileuton and montelukast were used.
상기 표 1에서 보는 바와 같이, 본 발명에 따른 치아시드 추출물은 양성대조군인 지루톤과 몬테루카스트와 비교시 동일 농도에서 5-리폭시게나제 억제 효과가 더 우수함을 알 수 있으며, 농도의존적으로 억제 활성 효과를 나타냄을 알 수 있다. 실시예 1 내지 3 중 실시예 1의 5-리폭시게나제 억제율이 가장 높은 것으로 확인되었다.As shown in Table 1, it can be seen that the chia seed extract according to the present invention has a more excellent 5-lipoxygenase inhibitory effect at the same concentration compared to the positive controls, i.d., seborrone and montelukast, and exhibits inhibitory activity in a concentration-dependent manner. indication can be seen. Among Examples 1 to 3, Example 1 was found to have the highest 5-lipoxygenase inhibition rate.
<실험예 2> 폐염증 억제 활성 평가<Experimental Example 2> Evaluation of pulmonary inflammation inhibitory activity
급성 폐염증 억제 활성을 평가하기 위해 양성 대조군으로 덱사메타손(Dexamethasone, DEX) 및 음성 대조군으로 무처리한 Vehicle을 사용하였다. 먼저, 체중 25~27 g의 수컷 ICR 마우스를 각 군당 7마리씩 나눈 뒤 마우스에 시험물질(100 mg/kg), 양성대조군(30 mg/kg)을 경구 투여하고 1시간 후에 LPS (Lipopolysaccharide) 2 mg/kg를 주입하고 BALF (BronchoAlveolar Lavage Fluid)를 수획하여 FACS 분석 평가하였다.Dexamethasone (DEX) was used as a positive control and an untreated vehicle as a negative control to evaluate the acute pulmonary inflammation inhibitory activity. First, male ICR mice weighing 25-27 g were divided into 7 mice per group, and the test substance (100 mg/kg) and the positive control group (30 mg/kg) were orally administered to the mice, and 2 mg of LPS (Lipopolysaccharide) was administered 1 hour later. /kg was injected and BALF (BronchoAlveolar Lavage Fluid) was harvested and evaluated by FACS analysis.
그 결과, 도 1을 참조하면, 실시예 1 내지 3의 조성물의 경우 폐로 유입되는 총 세포 수가 크게 감소함으로써 폐염증 억제 활성이 우수함을 확인하였다. 또한, BALF 내 대식세포(macrophage)와 호중구(neutrophil) 수 역시 실시예 1 내지 3의 추출물에서 유의미하게 감소하는 것을 확인하였다(도 2 및 도 3).As a result, referring to FIG. 1 , in the case of the compositions of Examples 1 to 3, it was confirmed that the total number of cells entering the lungs was greatly reduced, thereby exhibiting excellent lung inflammation inhibitory activity. In addition, it was confirmed that the number of macrophages and neutrophils in BALF was also significantly decreased in the extracts of Examples 1 to 3 (FIGS. 2 and 3).
<실험예 3> 거담작용 시험<Experimental Example 3> expectorant action test
거담 활성 평가를 위해, Engler 등의 방법(Engler H, Szelenyi I, J. Pharmacol. Methods. 11, 151~157, 1984; Bao-quin Lin et., Pulmonary Pharmacology & Therapeutics 21, 259~263, 2008;)을 이용하여, 하기와 같은 공정으로 실험을 수행하였다. 실험동물로는 6주령의 암컷 ICR 마우스를 각 군당 10마리씩 사용하였다. 양성대조군으로는 암브록솔염산염(Ambroxol HCl, Sigma)과 시네츄라시럽®을 사용하고, 음성 대조군으로는 무처리한 Vehicle을 사용하였다. 시험물질, 양성대조군, 음성대조군을 경구 투여하고, 30분 후 5% 페놀레드 300 ㎕(30 g 기준)를 복강 주사하였다. 30분 후, 디에틸이더(diethyl ether)를 이용해 마취시키고 복부 대동맥을 절단하여 방혈시킨 후, 기관(trachea) 전체를 절제하였다. 분리된 기관을 1 ml의 생리 식염수에 넣어 30분 동안 세척한 후 10,000 rpm으로 5분간 상온에서 원심 분리하였다. 분리된 상등액에 1 N 가성소다(NaOH)를 첨가(상등액 1 ml당 1 N NaOH 0.1 ml 첨가)한 후에 546 nm에서 흡광도를 측정하여 페놀레드의 농도로서 거담활성을 평가하였으며, 음성대조군(0.3% CMC 투여군)을 기준으로 객담 배출율(%)을 계산하여 하기 표 2에 나타내었다.For the evaluation of expectorant activity, the method of Engler et al. (Engler H, Szelenyi I, J. Pharmacol. Methods. 11, 151-157, 1984; Bao-quin Lin et., Pulmonary Pharmacology & Therapeutics 21, 259-263, 2008; ), and the experiment was performed in the following process. As experimental animals, 6-week-old female ICR mice were used, 10 in each group. Ambroxol hydrochloride (Ambroxol HCl, Sigma) and Synechura Syrup® were used as a positive control group, and an untreated vehicle was used as a negative control group. The test substance, positive control group, and negative control group were orally administered, and 30 minutes later, 300 μl of 5% phenol red (based on 30 g) was intraperitoneally injected. After 30 minutes, anesthetized with diethyl ether, cut the abdominal aorta, exsanguinated, and then excised the entire trachea. The separated organ was washed in 1 ml of physiological saline for 30 minutes and then centrifuged at 10,000 rpm for 5 minutes at room temperature. After adding 1 N caustic soda (NaOH) to the separated supernatant (adding 0.1 ml of 1 N NaOH per 1 ml of supernatant), the absorbance was measured at 546 nm to evaluate expectorant activity as the concentration of phenol red, and the negative control group (0.3% The sputum discharge rate (%) was calculated based on the CMC administration group) and is shown in Table 2 below.
상기 표 2의 결과로부터 알 수 있듯이 본 발명에 따른 치아시드 추출물은 동일 농도의 시네츄라시럽® 대비 높은 객담 배출율을 나타내는 것을 확인할 수 있으며, 실시예 1의 경우 시네츄라시럽®보다 약 2배 이상의 객담 배출율을 나타냄에 따라 월등히 우수한 효과를 지님을 알 수 있다.As can be seen from the results in Table 2, it can be seen that the chia seed extract according to the present invention exhibits a high sputum discharge rate compared to Synatura Syrup® of the same concentration, and in the case of Example 1, the sputum discharge rate is about twice or more than that of Synatura Syrup® As shown, it can be seen that it has a significantly superior effect.
<실험예 4> 기관지 수축 억제 시험(<Experimental Example 4> Bronchial contraction inhibition test ( in vitroin vitro ))
기관지 수축 억제 활성 여부를 확인하기 위해 하기 방법(Nature, 1977, 270, 256~257; Jpn. J. Pharmacol., 1996, 72, 1~8; Kor. J. Pharmacogn., 1999, 30[4], 377~383)을 이용하여 농도별 기관지 수축 억제 시험을 실시하였다.In order to confirm the bronchoconstriction inhibitory activity, the following method (Nature, 1977, 270, 256-257; Jpn. J. Pharmacol., 1996, 72, 1-8; Kor. J. Pharmacogn., 1999, 30 [4] , 377-383) was used to test the inhibition of bronchoconstriction by concentration.
먼저, 하틀리(Hartely)계 수컷 기니피그(400~500 g, BGI, 국내)에 항난알부민 항혈청(anti-ovalbumin anti-serum)을 2 ㎖/㎏의 부피로 정맥 주사하여 감작하였다. 감작 48시간 후 기니피그를 실혈 치사시킨 후 기관지를 적출하였다. 이후, 타이로이드(tyrode) 액상에서 기관지에 붙어있는 타조직을 제거한 후 연골이 2~3개 포함되도록 링 모양으로 절개하였다. 절개 후에는 기관지 근육을 보존하면서 링의 연골부분을 절개하고 양쪽으로 실을 연결한 후 장기욕조(organ bath)에 현수(suspension)하였고, 일정시간의 안정화 후 카르바콜(carbachol) 10 ㎍/㎖을 넣어 최대 수축을 유발하였으며, 타이로이드(tyrode) 액으로 기관지를 세척하고 안정화시켰다. 이후, 인도메타신(indomethacin) 5μM을 넣고, 1분 후 시험물질을 넣고, 5분 후 난알부민(ovalbumin) 20 ㎍/㎖을 넣어 수축을 유발하였다. 기관지 수축 억제율(%)은 카르바콜과 난알부민에 의한 수축을 비교하여 계산하였으며, 이에 대한 결과는 하기 표 3에 나타내었다. 기관지의 수축이완은 힘변환기(force transducer, WPI)와 연결된 생리 활성 측정기(powerlab 8/30, ADInstument)를 이용하여 측정하였다. 양성대조군으로는 롤리프람(Rolipram)을 이용하였다.First, Hartely male guinea pigs (400-500 g, BGI, Korea) were sensitized by intravenous injection of anti-ovalbumin anti-serum at a volume of 2 ml/kg. After 48 hours of sensitization, the guinea pigs were sacrificed by blood loss, and the bronchi were removed. Thereafter, other tissues attached to the bronchi were removed from the tyrode liquid phase, and then a ring-shaped incision was made to include 2 to 3 cartilages. After the incision, the cartilage part of the ring was incised while preserving the bronchial muscle, and the thread was connected on both sides, and then suspended in an organ bath. After stabilization for a certain time, 10 μg/ml of carbachol was added The maximum contraction was induced, and the bronchi were lavaged and stabilized with tyrode fluid. Thereafter, indomethacin (indomethacin) 5μM was added, the test substance was added after 1 minute, and ovalbumin (ovalbumin) 20 μg/ml was added after 5 minutes to induce contraction. Bronchoconstriction inhibition rate (%) was calculated by comparing the contraction caused by carbachol and ovalbumin, and the results are shown in Table 3 below. Bronchial contraction and relaxation were measured using a physiological activity measuring device (
상기 표 3에서 보는 바와 같이, 본 발명에 따른 치아시드 추출물은 양성대조군인 롤리프람과 비교시 같은 농도 대비 매우 우수한 활성을 나타내는 것을 확인할 수 있으며, 농도 의존적으로 효과를 나타내는 것을 알 수 있다. 상기 결과로부터 본 발명의 치아시드 추출물이 기관지 수축을 효과적으로 억제하는 것을 확인하였다.As shown in Table 3, it can be seen that the chia seed extract according to the present invention exhibits very excellent activity compared to the positive control, rolipram, at the same concentration, and exhibits the effect in a concentration-dependent manner. From the above results, it was confirmed that the chia seed extract of the present invention effectively inhibits bronchial constriction.
<실험예 5> 세포독성 분석<Experimental Example 5> Cytotoxicity analysis
세포생존율은 Mosmann 방법에 따라 MTT assay를 수행하여 측정하였다. Raw 264.7 cell을 96 well plate에 3×104 cells/well이 되도록 분주한 뒤 37℃, 5% CO2 incubator에서 배양하였다. 배양한 세포에 상기 실시예 1의 치아시드 추출물을 다양한 농도로 처리하여 18시간 동안 배양한 후, PBS (phosphate buffered saline)에 녹인 5 mg/ml의 MTT (3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide) 용액 50 ul를 각각의 well에 넣은 다음 37℃, 5% CO2 incubator에서 4시간 동안 배양하였다. 그 후 배양액을 제거하고, 형성된 formazan에 DMSO 100 ul를 각 well에 넣어 용해 한 후, 540 nm에서 흡광도를 측정하였다.Cell viability was measured by performing MTT assay according to the Mosmann method. Raw 264.7 cells were dispensed in a 96 well plate to be 3×10 4 cells/well, and cultured in a 37°C, 5% CO 2 incubator. The cultured cells were treated with the chia seed extract of Example 1 at various concentrations and cultured for 18 hours, and then 5 mg/ml of MTT (3-(4,5-dimethythiazol-2- 50 ul of yl)-2,5-diphenyltetrazolium bromide) solution was put into each well, and then incubated for 4 hours in a 37°C, 5% CO 2 incubator. Thereafter, the culture medium was removed, and 100 ul of DMSO was added to each well to dissolve the formed formazan, and the absorbance was measured at 540 nm.
그 결과, 도 4에서 보는 바와 같이 치아시드 추출물의 세포 생존율은 1 mg/ml에서 100 mg/ml 농도까지 90% 이상의 생존율을 보였다.As a result, as shown in FIG. 4, the cell viability of the chia seed extract showed a viability of 90% or more from 1 mg/ml to 100 mg/ml.
이상, 본 발명을 예시적으로 설명하였으며, 본 발명이 속하는 기술분야에서 통상의 지식을 가지는 자라면 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 다양한 변형이 가능할 것이다. 따라서, 본 명세서에 개시된 실시예들은 본 발명을 한정하기 위한 것이 아니라 설명하기 위한 것이고, 이러한 실시예에 의하여 본 발명의 사상과 범위가 한정되는 것은 아니다. 본 발명의 보호범위는 아래의 청구범위에 의해서 해석되어야 하며, 그와 동등한 범위 내에 있는 모든 기술은 본 발명의 권리범위에 포함하는 것으로 해석되어야 할 것이다.In the above, the present invention has been described as an example, and those skilled in the art will be able to make various modifications without departing from the essential characteristics of the present invention. Therefore, the embodiments disclosed in this specification are intended to explain, not limit, the present invention, and the spirit and scope of the present invention are not limited by these embodiments. The protection scope of the present invention should be construed by the following claims, and all techniques within the equivalent range should be construed as being included in the scope of the present invention.
Claims (8)
Pharmaceutical composition for prevention or treatment of phlegm, asthma or pneumonia containing chia seed ethanol or water extract as an active ingredient
The pharmaceutical composition according to claim 1, wherein the chia seed extract is included in an amount of 0.001 to 90% by weight based on the total weight of the composition.
Health functional food composition for preventing or improving sputum, asthma or pneumonia containing chia seed ethanol or water extract as an active ingredient
Feed composition for preventing or improving phlegm, asthma or pneumonia containing chia seed ethanol or water extract as an active ingredient
Feed additive composition for preventing or improving phlegm, asthma or pneumonia containing chia seed ethanol or water extract as an active ingredient
The feed additive composition according to claim 7, which is a powder, tablet, capsule, pill or liquid
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220029612A KR102469733B1 (en) | 2022-03-08 | 2022-03-08 | Composition for preventing or treating respiratory disease comprising chia seeds extracts |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220029612A KR102469733B1 (en) | 2022-03-08 | 2022-03-08 | Composition for preventing or treating respiratory disease comprising chia seeds extracts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102469733B1 true KR102469733B1 (en) | 2022-11-22 |
Family
ID=84236322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220029612A KR102469733B1 (en) | 2022-03-08 | 2022-03-08 | Composition for preventing or treating respiratory disease comprising chia seeds extracts |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102469733B1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080079162A (en) * | 2007-02-26 | 2008-08-29 | 김연진 | Assorted feedstuff composition containing chia seed or its extract, method of raising chicken using the same, and chicken meat acquired thereby |
| JP2018518451A (en) * | 2014-11-07 | 2018-07-12 | マゼ ジョリー ヴァダケムリ | Optimized fatty acid composition of nutrients |
-
2022
- 2022-03-08 KR KR1020220029612A patent/KR102469733B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080079162A (en) * | 2007-02-26 | 2008-08-29 | 김연진 | Assorted feedstuff composition containing chia seed or its extract, method of raising chicken using the same, and chicken meat acquired thereby |
| JP2018518451A (en) * | 2014-11-07 | 2018-07-12 | マゼ ジョリー ヴァダケムリ | Optimized fatty acid composition of nutrients |
Non-Patent Citations (2)
| Title |
|---|
| BMC Pulmonary Medicine. 2019. Vol.19, Article 97. * |
| J Biom Biotechnol. 2012. Vol.2012, Article ID 171956. * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102006738B1 (en) | Pharmaceutical Composition comprising extracts of Justicia procumbens L. for prevention or treatment of respiratory diseases | |
| KR101346244B1 (en) | Composition for preventing or relieving alcohol-induced hangover comprising medicinal herbs | |
| KR100860080B1 (en) | Pharmaceutical composition comprising the plant extract belonged to Veronica genus having anti-inflammatory, anti-allergic and-asthmatic activity | |
| KR101751398B1 (en) | Composition comprising Angelica gigas Nakai, Cornus officinalis, Cervi Parvum Cornu, Red ginseng, Rehmanniae Radix Preparata, Aquilaria agallocha Roxburgh and Honey for anti-inflammation | |
| KR101464337B1 (en) | Composition for anti-obesity comprising extract of Diospyros lotus as effective component | |
| KR101397841B1 (en) | Composition for Prevention or Treatment of Inflammatory Pulmonary Diseases Comprising Alisma orientale extract | |
| KR20130020095A (en) | Hepatoprotective composition containing stauntonia hexaphylla extract | |
| KR102169920B1 (en) | A composition comprising extract of Schisandra chinensis, pear and Platycodon grandiflorum for preventing or treating respiratory inflammatory diseases | |
| KR101930277B1 (en) | Composition for Preventing and Improving Hangover | |
| KR20210020050A (en) | Herbal Composition for Preventing or Treating Respiratory Disease | |
| KR101829637B1 (en) | A composition for improving, preventing and treating digestion dysfunction, leukocyte reduce, bone marrow suppression by side effects after anti-cancer therapy comprising Rhus verniciflua stoke extract | |
| KR102252126B1 (en) | Composition for prevention or treatment respiratory diseases comprising combination extracts of Chrysanthemum morifolium Ramatuelle and Scutellaria baicalensis as an active ingredient | |
| KR20160081359A (en) | A pharmaceutical composition for treating or preventing respiratory disease comprising combined herbal extracts | |
| KR102189109B1 (en) | A composition for improving, preventing and treating of asthmatic containing oriental medicine herbs oil extract as an active ingredient | |
| KR102469733B1 (en) | Composition for preventing or treating respiratory disease comprising chia seeds extracts | |
| KR20080008929A (en) | Health care food composition comprising oroxylin a for preventing or improving cognitive dysfunction | |
| KR101119410B1 (en) | Foeniculum vulgar extracts compositions for treating or preventing inflammatory diseases | |
| US20220273743A1 (en) | Composition for prevention, alleviation, or treatment of respiratory disease | |
| KR20190083769A (en) | Compositions for preventing or treating respiratory diseases containing Lionicerae Flower extract | |
| WO2015122728A1 (en) | Anti-tuberculosis composition for treating and preventing tuberculosis comprising melia azedarach l. extract or lobelia chinensis lour extract and fractions thereof | |
| KR20120086262A (en) | Fraxinus rhynchophylla Hance extracts compositions for treating or preventing inflammatory diseases | |
| KR101131719B1 (en) | Pulsatilla koreana extracts compositions for treating or preventing inflammatory diseases | |
| KR20190023236A (en) | An extract of Coptidis Rhizoma extracted with acetone, or a mixture of acetone and water | |
| KR102496752B1 (en) | Fruits of Acanthopanax Sessiliflorus extract including alcoholic liver injury prevention functional ingredients and method for manufacturing it | |
| EP2586451B1 (en) | Composition for preventing and/or alleviating hangover comprising extracts of Sophora flavescens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AMND | Amendment | ||
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |